Proton Pump Inhibitors

Stewardship of Proton Pump Inhibitors: Considerations for Use and Deprescribing

An on-demand article that promotes effective and safe prescribing of proton pump inhibitors.

  • Contact hours: 1.0 (0.10 CEU)
  • Registration is free of charge

Activity Description

Long-term use of proton pump inhibitors (PPIs) without an ongoing indication or evidence of benefit contributes to increased pill burden, increased medication-related costs, and potential adverse effects. This written article reviews FDA-approved labeling for PPIs, summarizes treatment guidelines regarding appropriate dosage and duration of treatment, and is designed to help learners identify appropriate indications for long-term use of PPIs. In the absence of an indication for long-term use, recommendations are provided to assist with developing patient-specific plans to deprescribe PPIs and manage symptoms.

Learning Objectives
 
  1. Identify the appropriate dosing and duration of PPIs based on FDA-approved indications and guideline recommendations.
  2. Discuss considerations for long-term PPI therapy.
  3. Determine when deprescribing of PPIs is appropriate based on patient-specific factors. 
Activity Contributors
Brenda Basile, PharmD, MS
Research Scientist
University at Buffalo School of Pharmacy and Pharmaceutical Sciences
 
Edward M Bednarczyk, PharmD, FACCP, FAPhA
Director, cHOPE
University at Buffalo School of Pharmacy and Pharmaceutical Sciences
 
Holly V Coe, PharmD
Clinical Assistant Professor
University at Buffalo School of Pharmacy and Pharmaceutical Sciences
 
Marsha Nelson
Associate Director, Office of Continuing Pharmacy Education
University at Buffalo School of Pharmacy and Pharmaceutical Sciences
 
Barbara Rogler, PharmD, MS
Clinical Assistant Professor
University at Buffalo School of Pharmacy and Pharmaceutical Sciences
 
Alexia Sroka, PharmD, BCPS
Coordinator, MPEP
University at Buffalo School of Pharmacy and Pharmaceutical Sciences
 
Intended Audience

Physicians, physician assistants, nurse practitioners, pharmacists, and other healthcare providers.

Cost and Registration

There is no fee for this activity. The program is supported by the New York State Department of Health Medicaid Prescriber Education Program (MPEP).

Accreditation and Certification Information

For physicians/providers:

Accreditation: The University at Buffalo Jacobs School of Medicine and Biomedical Sciences is accredited by ACCME to provide continuing medical education for physicians.

Certification: The University at Buffalo Jacobs School of Medicine and Biomedical Sciences designates this internet enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit (TM). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For pharmacists: 

The University at Buffalo School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based activity has been assigned ACPE # 0044-0000-23-033-H01-P and will award 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Credit will be uploaded to the CPE Monitor for those who complete all components of this activity.

Activity Components for Continuing Education Credit
To obtain continuing education credit, register and complete the required materials. This continuing education activity contains a pre-test, written article, post-test, and program evaluation. Credit will be awarded upon successful completion of the post-test activity, with a score of 70% or better.
 
Initial release date: 8/14/2023
Expiration date: 8/13/2026
Educational Content